This study aims to evaluate whether luspatercept can improve the efficacy and safety of anemia treatment in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation.
1. Diagnosis of malignant hematological tumors and undergoing allogeneic hematopoietic stem cell transplantation.
2. Expected survival after transplantation exceeds 1 month.
3. Age 18-60 years.
4. Hemoglobin ≤60 g/L on day 0 after transplantation.
1. Uncontrolled infection at the time of enrollment, or requiring mechanical ventilation or hemodynamic instability;
2. Severe organic damage: hepatic or renal impairment;
3. Occurrence of any of the following within 6 months prior to the study: myocardial infarction, severe/unstable angina pectoris, congestive heart failure, or cerebrovascular accident, including transient ischemic attack;
4. Presence of psychiatric disorders or other conditions that may compromise compliance with study treatment and monitoring requirements. Failure to sign the informed consent form;
Single group
Luspatercept
DrugSubjects will be screened according to the inclusion and exclusion criteria. Eligible patients enrolled will receive treatment with Luspatercept at a dose of 1.0 mg/kg, administered subcutaneously as a single dose on day +3 after transplantation.
Cumulative volume of red blood cell transfusions
Cumulative volume of red blood cell transfusions
Platelet and neutrophil counts
Incidence of poor graft function (PGF).
Serum/bone marrow GATA1,and GDF11 levels
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
